IL15 and neoplasm: To date, therapies that aim to harness the anti-tumor function of NK cells have involved either the adoptive transfer of ex vivo expanded NK cells, with or without genetic modification [15,16,17,18], or the promotion of in vivo NK cell activation through the administration of recombinant proteins, such as interleukin-15 (IL-15) superagonists [19,20].